How long can kidney cancer spread to live?

summary

Renal malignancy, also known as renal adenocarcinoma or renal cell carcinoma, requires patients to maintain enough attention to receive the treatment of this disease. It originated from the renal tubular epithelial system, accounting for 3% of the adult malignant tumors. The incidence rate of urinary malignancies is second, second only to bladder cancer, accounting for 85% of the total renal malignancies. It includes various subtypes originated from urinary tubules. According to the relevant research reports, the incidence rate of renal cell carcinoma is increasing at 2% annually worldwide. Over 20 million new renal cell carcinoma and over 100 thousand deaths from renal cancer are increasing every year. The incidence rate of renal cell carcinoma is also increasing in China, which seriously threatens human health. So we must do a good job in the related work of this disease, so how long can the spread of renal malignant tumor live?.

How long can kidney cancer spread to live?

First, the average survival time of patients with renal malignant tumor was 47.64 months, and the median survival time was 154 months. The median survival time of patients with different factors was 13 months, which was lower than 228 months of patients with surgery, 20 months of patients with high TNM stage, 227 months of patients with low TNM stage, 135 months of patients with cancer concealment, 227 months of patients with cancer notification, and 56 months of patients in primary and secondary hospitals, It was lower than 312 months in the third grade hospital. Concealment of tumor status, diagnosis and treatment in low grade hospital, high TNM stage of tumor and no choice of surgical treatment were independent risk factors for decreased overall survival rate of renal cell carcinoma.

Second: how to prolong the life of patients can give patients vitamin selenium: clinical are combined with Hecun malt selenium capsules to cancer patients, selenium is known as the "king of cancer". In September 2003, the U.S. Food and Drug Administration (FDA) recognized selenium as an anti-cancer agent, which is the official medical statement of the U.S. government that selenium can inhibit cancer. Some scientists supplement selenium to cancer patients for a long time, which reduces the death rate of cancer patients by 50%. A large number of studies have shown that selenium is a powerful tumor inhibitor, which can inhibit the growth of cancer cells and block the energy supply of cancer cells. At present, many scholars believe that selenium is not only effective in cancer prevention, but also can be used as adjuvant of chemotherapy to reduce the side effects of chemotherapy drugs and increase drug tolerance.

Third, the level of serum selenium is also related to the recurrence rate, degree of spread, survival time and prognosis of cancer The tumor patients with higher blood selenium level may be limited to the primary site, less likely to have distant metastasis, lower recurrence rate and better prognosis. On the contrary, patients with significant decrease of serum selenium have the possibility of distant metastasis, high malignancy and short survival. The selenium content of cancer patients is lower than that of normal people. Hecun malt selenium capsule is suitable for cancer patients because of its high selenium content.

matters needing attention

It is an effective measure to improve the survival time of renal cancer patients to strive for early detection of tumor, select high-level hospitals and carry out surgical treatment as far as possible, and respect the right to know of renal cancer patients.